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Abstract
Background: One of the top three research priorities for the UK clinical trial community is to address the gap in evidence-
based approaches to improving participant retention in randomised trials. Despite this, there is little evidence supporting
methods to improve retention. This paper reports the PRioRiTy II project, a Priority Setting Partnership (PSP) that identified
and prioritised unanswered questions and uncertainties around trial retention in collaboration with key stakeholders.
Methods: This PSP was conducted in collaboration with the James Lind Alliance, a non-profit making initiative, to support
key stakeholders (researchers, patients, and the public) in jointly identifying and agreeing on priority research questions.
There were three stages. (1) First an initial online survey was conducted consisting of six open-ended questions about
retention in randomised trials. Responses were coded into thematic groups to create a longlist of questions. The longlist
of questions was checked against existing evidence to ensure that they had not been answered by existing research. (2)
An interim stage involved a further online survey where stakeholders were asked to select questions of key importance
from the longlist. (3) A face-to-face consensus meeting was held, where key stakeholder representatives agreed on an
ordered list of 21 unanswered research questions for methods of improving retention in randomised trials.
Results: A total of 456 respondents yielded 2431 answers to six open-ended questions, from which 372 questions
specifically about retention were identified. Further analysis included thematically grouping all data items within answers
and merging questions in consultation with the Steering Group. This produced 27 questions for further rating during the
interim survey. The top 21 questions from the interim online survey were brought to a face-to-face consensus meeting in
which key stakeholder representatives prioritised the order. The ‘Top 10’ of these are reported in this paper. The number
one ranked question was ’What motivates a participant’s decision to complete a clinical trial?’ The entire list will be
available at www.priorityresearch.ie.
Conclusion: The Top 10 list can inform the direction of future research on trial methods and be used by funders to
guide projects aiming to address and improve retention in randomised trials.
Keywords: Trials methodology, Retention challenges, Participation in randomised trials, Participant retention, Priority
Setting Partnership, James Lind Alliance, Patient and public involvement
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Background
Randomised trials are essential for evidence-based health
and social care, though many struggle to recruit and retain
participants. This poses significant problems for the overall
reliability and generalisability of results when recruitment
goals are missed or participants are lost to follow-up. One of
the top three priorities for research into randomised trials,
as set out by the UK clinical trials community, is to address
the gap in evidence-based approaches to improving
retention in randomised trials [1]. This Priority Setting Part-
nership (PSP) addresses this subject by investigating un-
answered research questions on how to improve retention
in randomised trials. Many trial participants drop out before
trial completion, sometimes in excess of 20%, and 50% of tri-
als in the UK have a loss to follow-up of more than 11% [2].
As retention within a trial decreases, so too does its credibil-
ity and our ability to say with confidence that the results are
accurate. This also affects the trial’s ability to contribute to-
wards changes in clinical practice. Without any improve-
ments to retention, trials may be hindered in both their
applicability and ability to guide evidence-based care [3].
Despite this, there is currently little evidence other than
anecdotal accounts about how to improve retention in
randomised trials— as opposed to improvements to re-
cruitment, for which there is substantial evidence. Simi-
larly, the Cochrane review on trial retention at present
only has evidence relating to financial incentives to return
postal questionnaires and use of second-class versus first-
class postage. It also does not include interventions de-
signed specifically to address an individual’s reasons for
dropping out of a trial [4]. Current strategies to improve
retention in randomised trials could be bolstered by this
collaborative PSP, as current guidance is limited to pri-
mary care trials only [5] or has been developed without
equal patient involvement [6, 7]. To address this, further
investigation was necessary with a wider range of stake-
holders involved to identify research uncertainties.
These uncertainties about how to retain participants
mean that at present sample sizes of trials tend to be in-
creased in anticipation of a loss to follow-up. In addition,
many Clinical Trial Units and Chief Investigators use
strategies to compensate for missing data with little evi-
dence to support their effectiveness [7]. Around 50% of
trials fail to reach their recruitment targets [2], and the
average cost of a clinical trial in the UK per participant is
around £8500 [8]. Countering loss to follow-up through
increases to sample size uses resources that could other-
wise be put to better use. Collecting insufficient data to
address the aims of a trial reduces our ability to make
meaningful use of the generosity of trial participants who
enter trials in good faith. It is therefore not only financially
prudent to improve trial retention, but important from an
ethical perspective in order to reduce research waste and
provide better care [9].
For these reasons, there is an urgent need to conduct
further research into trial retention. Moreover, this re-
search should be focussed on the areas considered essen-
tial to stakeholders who are involved directly. This paper
outlines the areas of research that key stakeholders believe
should be the focus of future efforts to improve retention
in randomised trials. We have defined non-retention as in-
stances in which participants are prematurely ’off-study’,
such as withdrawal of consent or loss to follow-up, and
therefore outcome data cannot be obtained. This is in line
with the Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) guidelines [10]. This re-
search builds on the methodological framework used in
the Prioritising Recruitment in Randomised Trials (PRioR-
iTy I) project [11], which used a James Lind Alliance
(JLA) PSP to identify the top priorities for research into
participant recruitment to randomised trials. The JLA
method of bringing together relevant stakeholders to de-
cide on research priorities has been used extensively for
setting clinical research priorities [12, 13]. However, the
application of the JLA method to methodological research
is a recent development first utilised in PRioRiTy I [11].
Prioritising Retention in Randomised Trials (PRioRiTy II)
viewed the involvement of patient partners in the govern-
ance of the project as an integral and essential part of our
whole approach. This PSP built and expanded on the PRi-
oRiTy I study by adding more members to the Steering
Group. The patient partners included individuals who were
new to research methodology as well as some trials
methodology-experienced representatives. The decision to
supplement the patient partners group with those with less
experience of trials methodology research was to ensure that
the project continued to ‘talk to’ the wider patient popula-
tion and link in to networks of said partners who may not
have previously been involved in trial methodology research.
Methods
The methods are described in full in the following sec-
tions, but as a brief overview, this PRioRiTy II PSP
followed the same overall method as that used during the
PRioRiTy I PSP [11]. Key stages included an initial stage
that consisted of data collection and analysis to generate a
list of unanswered questions. This led onto an interim
stage that generated an indicative question list for use in
the interim survey. The project then culminated in bring-
ing 21 questions from the indicative list to a final consen-
sus meeting to agree on the top priorities for future
research into trial retention. These priorities are uncer-
tainties raised by the stakeholders and judged to be un-
answered by existing evidence. All three stages of this
project were open to anyone over the age of 18 years who
had been involved in randomised trials in the UK and
Ireland. For better precision during data collection, seven
categories were given as options to describe the role of the
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stakeholders during the initial survey. For the remainder
of the project, we combined stakeholder roles and orga-
nised them into the following four groups:
 Patient or member of the public involved in a trial
(as a participant or parent/carer of a participant or
as a contributor to design/delivery of trial)
 Frontline staff or other staff involved in trial
retention (e.g. Research Nurse, Trial Manager,
regulatory or oversight role such as Sponsor or
Research Director)
 Investigator (e.g. Chief Investigator, Principal
Investigator, Co-investigator)
 Trial methodologist
This PSP did not consider uncertainties relating to adher-
ence to trial interventions. The objectives of the PSP were to:
 Bring the public, clinicians, and researchers together
to identify unanswered questions around retention
in randomised trials
 Agree by consensus on a prioritised list of those
unanswered questions which will be used to inform
future research.
Steering Group
We established a Steering Group to oversee the PSP in ac-
cordance with JLA guidance and held the first meeting in
January 2018. The Steering Group was composed of 24
members: 6 patient partners (3 with experience of trials
methodology research and 3 without), 6 frontline staff or
other staff involved in trial retention, 5 investigators, 5 trial
methodologists, and 2 JLA representatives. Contributors
were identified through known personal contacts and key
members working in trial retention and invited to join the
Steering Group. At the first Steering Group meeting a gap
analysis of representation was conducted and efforts made
to purposefully fill those gaps through active recruitment,
e.g. Twitter adverts for patient partners and direct contacts
of known research staff. Membership reflected the range of
stakeholders with whom we wished to engage during the
PSP. Drawing on members’ expertise and networks, the
Steering Group helped identify and recruit stakeholders
during each stage. We also held regular meetings to ensure
that the work proceeded to agreed timetables and to con-
tinue engagement and momentum. The JLA was also rep-
resented on the Steering Group to ensure that the process
adhered to JLA principles.
Initial online survey
Identification of stakeholders and development of initial survey
Convenience sampling was used to sample survey respon-
dents. Steering Group members, including the patient part-
ners, identified and engaged a wide range of appropriate
potential stakeholders through their networks of contacts.
The target population mirrored those groups represented
by individuals on the Steering Group. Specifically, these
were patients or members of the public involved in a trial,
frontline staff or other staff involved in trial retention, inves-
tigators, and trial methodologists, all of whom needed to be
based in the UK or Ireland and be over 18. We developed
an eight-question online survey in SurveyMonkey (Survey-
Monkey, Palo Alto, CA, USA) to gather uncertainties for
our initial stage. This was open for 4 weeks. We also made
a paper copy of the survey with pre-paid return envelopes
available if required. We set no formal target sample size
for the number of responses. The eight questions included
six open-ended questions (Appendix 1) that explored the
respondent’s views on unanswered questions for trial reten-
tion and general comments relating to retention in rando-
mised trials that stakeholders would like to see answered.
Based on the experience of the PRioRITy I project and dis-
cussion by the project Steering Group, these six open-
ended questions were modelled on broad areas of trial re-
tention: why participants stay involved; planning of data
collection; processes of collecting data; information pro-
vided about data collection; aspects relating to trial staff in-
volved in data collection; any other comments. It was felt
that using six questions rather than one generic question
may allow broader coverage of all aspects of trial retention.
The questions also included an additional two demographic
questions about the respondents to help monitor the geo-
graphic spread and roles of people responding to the sur-
vey. A pilot to test question comprehension and website
usability was conducted with a small sample (n = 6) of vol-
unteers from within the Health Services Research Unit
(HSRU) but included non-academic staff members. We
then distributed a weblink to the survey to the four stake-
holder groups (described earlier) and also promoted the
survey through social media channels and Twitter hashtags.
The initial survey was launched in March 2018 and closed
in May 2018 (8 weeks of data collection). We also asked re-
spondents if they would consider attending the final con-
sensus meeting. Electronic data was stored on password-
protected university computers supported by secure servers.
Paper copies of questionnaires were stored in locked tam-
bour filing systems. The electronic and paper data was held
in locked offices and only accessible by key personnel.
Coding and analysing responses
The initial survey was hosted by the JLA, who provided the
Steering Group with regular updates and the compiled an-
swers once completed. We used samples of responses as
they were returned to us to identify key themes and ques-
tions. This allowed us to generate a representative series of
thematic groups efficiently once the survey closed. The JLA
collated the survey responses into a single Excel spreadsheet,
and we coded the responses using a process of constant
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comparison analysis [14] into a thematic group where ap-
propriate. We repeated this process of comparison until the
range and number of thematic groups truly reflected the
whole data set. The determination of thematic groups was
an iterative process and generated through discussion
amongst the Aberdeen team members, who also conducted
the subsequent analysis (DB, HG, KG, and ST). Where an
item did not fit into an existing thematic group, we either
expanded a thematic group or created a new one. Each
stakeholder response could contain numerous items, and
multiple themes may have arisen. We therefore sub-divided
responses into constituent parts during coding to allow their
mapping across different thematic groups. We did not as-
sign responses that were out of scope to a thematic code; ra-
ther, we categorised these responses separately for potential
future use. All responses that did not refer to a process
(such as recruitment) were assumed to be about retention
as per the survey questions and hence were considered to
be within scope. This process also involved regular group
discussion and consultation to ensure consistency in ap-
proach and accuracy of the coding.
Once coded, we analysed the data to determine the
initial sub-questions and broader main questions
present within each theme as well as how often they
occurred over the course of 4 weeks. To guide this
process, we used word-for-word responses as a frame-
work for developing the sub-questions, which grew it-
eratively as the data was analysed. We compiled the
broader questions from each theme together and con-
ducted a check to ensure that they remained repre-
sentative of their respective sub-questions. To
evaluate reliability, once we connected all coded data
items to sub-questions, a 10% sample was selected at
random from each team member’s analysis to com-
pare findings. We held group discussions to identify
discrepancies and resolve disagreements. We also con-
ducted a check with the questions identified in the
initial scoping survey against existing sources of evi-
dence reporting trial retention research. This ensured
that questions raised for the interim stage were un-
answered by research. The evidence sources used for
checking were:
1. The Cochrane review of interventions to improve
retention in trials, with the 2012 search updated by
members of the Aberdeen team (October 2017) and
screened [4]
2. A qualitative synthesis of barriers and facilitators to
participant retention in trials [15]
3. A systematic review of non-randomised evaluations
of interventions to improve retention in trials, with
members of the PRioRiTy II team actively involved
as reviewers ([16], with completed review submitted
for publication).
Together with the Steering Group, we grouped and
merged the longlist of broad questions where appropriate
and removed duplicates to create a shortlist of questions
in advance of the interim stage. Through consultation
with the Steering Group, we discussed and sometimes re-
vised the terminology to improve the clarity of the original
meaning of the questions whilst ensuring the items
remained true to the voices of respondents.
Interim priority setting stage
Development of the indicative question list and interim survey
In the interim stage, we conducted a ‘back-categorisa-
tion’ on the initial stage shortlist in which we asked for
feedback and comments from stakeholders who were
not involved in the project. These individuals were iden-
tified through two processes: (1) email invitation to
members of the HSRU (i.e. people who were familiar
with trials); (2) invitation to friends and family (who
were not familiar with trials) of the Aberdeen team. This
process of back-categorisation involved presenting stake-
holders with the shortlist of questions from the previous
stage and conducting short individual interviews to as-
sess their understanding of the questions. We also asked
individuals involved in the back-categorisation process
to provide examples of the types of research activities
they would expect to see covered by each question. This
process ensured that the language used was broad
enough to ensure the correct coding of sub-questions
under broader indicative questions. For example, ques-
tioning around the broad question ‘How could technol-
ogy be best used in trial follow-up processes?’ included
probing stakeholders on what their understanding of
‘technology’ is in relation to trials. Open questions such
as ‘From this question, who might you assume would be
using technology within trial follow-up processes?’ were
used to gather responses to assess whether the question
was unintentionally focussing on one specific group of
trial stakeholders (e.g. patients). In this example, individ-
uals explained that technology could be used by both
the people involved in doing the trial (e.g. research
nurses, clinicians) and the people taking part in the trial,
so the language of the question was not changed.
The results of the back-categorisation were combined
with the earlier responses from the Steering Group to cre-
ate the list of indicative questions for the interim survey.
For the interim survey, we used SurveyMonkey to ask
stakeholders to choose up to 10 of the questions that they
believed were the most important. This survey was open
for 6 weeks, and we made paper copies of the survey avail-
able if required. Invitations to this survey were open to any-
one, and not restricted to the participants from the initial
survey. As with the initial survey, no formal target sample
size was set. However, the number of respondents within
each reported group was checked weekly. This allowed us
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to target groups with lower representation during the on-
going dissemination of the survey.
We distributed the survey link through email, institu-
tion websites, blogs, newsletters, and social media. The
HSRU at the University of Aberdeen also issued a press
release and coordinated promotion alongside the JLA.
The interim survey was launched in August 2018 and
closed in September 2018 (6 weeks of data collection).
Voting and ranking interim survey items
The online survey included a drop-down menu showing
the indicative question list from which no more than 10
could be selected. This generated a total score for each
question to represent the overall number of times the
question was selected. We also used ranked weighted
scores to decide which of the interim survey research
questions would be taken forward to the final consensus
meeting, using the following standard JLA approach as
described in the JLA Guidebook [17] (www.jla.nihr.ac.
uk/jla-guidebook/).
Each time a question was chosen, we assigned it one
point. To ensure equal influence, points for each
stakeholder group were tallied separately, generating
separate total scores for each group for the questions.
Within each of the four stakeholder groups, the scores
for each question were arranged in order from highest
to lowest. We then gave these a new score according
to their position, from 27 for the most popular ques-
tion down to 1 for the least popular. This resulted in
the lowest ranked question receiving the lowest total
score, through to the highest ranked question receiv-
ing the highest. The list was then ordered by score
from highest to lowest and presented to the Steering
Group. In cases when the questions had the same
total, we ranked them in joint place. This gave the
overall interim ranking to the research questions and
the rankings for each of the stakeholder groups, whilst
minimising bias owing to numbers of responses from
each stakeholder group.
Consensus meeting
The final prioritisation consensus meeting was a one-day
event held in Birmingham, UK, in October 2018 to iden-
tify and agree on a ‘Top 10’ list of research questions. We
brought together representatives from the key stakeholder
groups (in roughly equal numbers) to determine the Top
10 list of priorities from the top 21 questions from the in-
terim survey. The consensus meeting followed the stand-
ard approach described in the JLA Guidebook, namely
using small and whole group discussions in a face-to-face
meeting with a particular emphasis on the Top 10 [17]
(www.jla.nihr.ac.uk/jla-guidebook/). We remunerated pa-
tient participants for their time according to INVOLVE
UK guidance, and travel expenses for all attendees were
reimbursed. Members of the Aberdeen team planned and
organised the event alongside members of the JLA.
The consensus meeting was a full day of plenary and
small group discussion, chaired by a JLA Senior Adviser.
All attendees were provided with the list of 21 questions
in advance of the meeting, to allow time to familiarise
themselves with the questions and consider their thoughts
on the importance of each one. A JLA facilitator led each
of three small groups, which consisted of even representa-
tion of the stakeholder groups. The JLA facilitators acted
as neutral guides for the process and ensured equal par-
ticipation in order to minimise authority effects. After an
introductory plenary session with the entire group, the
three small groups were convened and asked to discuss
and prioritise all the listed questions. To support the dis-
cussions, individual question cards were used with ex-
ample quotes from related initial survey responses to
provide context. Tri-colour segmented tables were used
(red, amber, and green) to represent areas of increasing
importance, with red meaning less important and green
meaning most important. These initial small groups were
then mixed for the second round of discussion and priori-
tisation to ensure exposure to a range of ideas and elimin-
ate the potential bias of group think. Finally, the small
groups all came back together in a plenary session to agree
on the final prioritised list.
Results
Initial survey
The initial survey was completed by 456 respondents
with 454 (99%) answering at least one open-ended feed-
back question. Only three people requested a paper copy
of the initial survey. Completion of the initial survey
questions is shown in Table 1.
Demographic information: initial survey
The most frequently reported role amongst initial re-
spondents was a researcher involved in aspects of trials
other than retention (22%). The proportion of respon-
dents within each stakeholder group and the geograph-
ical spread are shown in Table 2.
Initial stage: collating themes and merging questions
Thematic grouping was used to sort and separate data from
the 2431 answers from 456 responses into categories,
resulting in 3256 individual coded items. Within this there
were 372 specific questions about retention that served as
templates to create a series of sub-questions which would
later be grouped within and constitute the main questions,
depending on how often they appeared within the data.
This allowed each coded item to be represented with a
question and led to the creation of a longlist of 105 total
questions through combining overlapping main and sub-
questions. Through review and discussion with the Steering
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Table 1 Completion of initial survey
Demographic questions Number Completed (%)
Consent to participate (yes) 456 100%
Age (range) 452 99%
Respondent’s role in trials 450 99%
Where respondent lives 452 99%
Specific open-ended feedback questions
Based on your experience, what questions or comments do you have
(if any) about why people stay involved in a trial?
454 99%
Based on your experience, what questions or comments do you have
(if any) about the planning of study data collection?
415 91%
Based on your experience, what questions or comments do you have
(if any) about how trials collect follow-up data from participants?
397 87%
Based on your experience, what questions or comments do you have
(if any) about the information people are given about follow-up data
collection procedures for a trial?
376 82%
Based on your experience, what questions or comments do you have
(if any) about trial staff who are involved in collecting follow-up data
from trial participants?
343 75%
Do you have any other questions or comments about how people
are encouraged to stay involved in trials?
261 57%
Table 2 Initial survey respondent roles
Number Percentage
Which one of the following best describes your main role in a randomised trial?
A researcher involved in aspects of the trial other than retention 96 22
A principal investigator 95 21
A person invited to take part in a trial 70 15
A trial methodologist (someone who specialises in the methods of how trials
are designed, run, analysed, and reported)
70 15
A researcher involved in encouraging people to stay involved in trials 65 14
A patient, carer, or public contributor to the design or running of trials 22 5
Other (please describe) 19 4
A parent or carer of a person invited to take part in a trial 10 2
No response 9 2
Total 456 100
Where do you usually live?
England 281 62
Scotland 61 14
Republic of Ireland 51 11
Wales 33 7
Other 15 3
Northern Ireland 11 2
No response 4 1
Total 456 100
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Group, we merged questions from this list where there was
substantial overlap to a shortlist of 33 questions to be car-
ried over to the interim stage.
Interim stage
Completion of interim survey
With further consultation and the ‘back-categorisation’
process, we reduced the initial question shortlist to an
indicative list of 27 questions to be used in the interim
survey. The survey received 886 responses overall. Of
these, only 1 was on paper and 16 were not answered
fully. The following results therefore report data from
870 responses. Of these, 100% made a selection of up to
10 of the 27 questions, and 864 respondents gave infor-
mation describing their gender, with 650 (75%) selecting
female and 205 (24%) selecting male, 1 using their own
term and 8 (1%) preferring not to say.
Demographic information
The spread of stakeholder groups and their geographical
spread can be seen in Table 3.
Interim survey ranking progress
Following the standard JLA approach for analysis of the
interim survey [17], a ranked weighted score across all
stakeholder groups was used to select the top 21 questions
to be taken to the consensus meeting. We made this deci-
sion as experience from the JLA suggests between 20 and
25 questions are optimal for discussion. We selected 21
rather than 20 because there was a tie between the rank-
ings, where two questions received the same score.
Consensus meeting
The consensus meeting consisted of 30 stakeholders across
the four groups, comprising 12 patients, 9 clinicians, and 9
total researchers and other staff. Some of the patient part-
ners from the Steering Group attended the meeting as ob-
servers. Three JLA facilitators, including one who acted as
chair, were present at the meeting in addition to 10 ob-
servers from the Steering Group. The consensus meeting
culminated in a plenary session involving all the stake-
holders. This finalised the ordering of the questions, created
the Top 10 list shown in Table 4, and ranked the remaining
questions (11–21, Appendix 2). All are available online at
www.priorityresearch.ie.
The process of this PSP from data collection to the
final priority question list is illustrated in Fig. 1.
Link to PRioRiTy I
During the course of this PSP, there were many similar-
ities between our findings and those from PRioRiTy I.
Of our final Top 10 questions generated at the consen-
sus meeting, five share a thematic area with questions
within the PRioRiTy I PSP’s top 10 questions for recruit-
ment. These have been highlighted in Table 5 alongside
their respective ranking in each PSP.
Availability of the research question list
The entire list of prioritised questions from the PRioRiTy
II project will be available online, alongside the results
from the PRioRiTy I project into recruitment, on a dedi-
cated website (www.priorityresearch.ie). This was created
initially by the Health Research Board-Trials Methodology
Research Network Ireland (HRB-TMRN) and expanded to
include the results of this PSP. Questions can be viewed
Table 3 Interim survey respondent roles
Number Percentage
Which one of the following best describes your main role in a randomised trial?
Frontline staff or other staff involved or invested in trial retention (e.g. Research
Nurse, Trial Manager, regulatory or oversight role such as Sponsor or Research Director)
403 46
Investigator (e.g. Chief Investigator, Principal Investigator, Co-investigator) 225 26
Patient or public member involved in a trial (as a participant or parent/carer
of a participant, or as a contributor to design/delivery of trial)
174 20
Trial methodologist 68 8
Total 870 100




The Republic of Ireland 51 6
Other 30 3
Northern Ireland 19 3
Total 864 100
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by their ranked importance or by thematic category.
Teams undertaking research in the areas of these ques-
tions are asked to submit details of their work to the
HRB-TMRN through the preceding linked website.
Discussion
Alongside the PRioRiTy I project, we believe the results
of this PSP can contribute towards future efforts to re-
duce research waste and help ensure that the voice of
key stakeholders, required to improve retention, is
reflected in the direction of future research. Participation
was restricted to within the UK and Ireland to ensure
that the results were directly applicable in those coun-
tries. Therefore, responses from other countries were
not used for the final analysis, though international col-
laboration could help identify common retention issues
across randomised trials in different contexts.
As mentioned previously, two linked pieces of work have
also developed research agendas within trial retention. The
first focussed on developing best practice guidance for the
use of retention strategies in primary care trials and built
on the findings from the Cochrane review on interventions
to improve trial retention [7]. This ‘best practice’ document
provides some interesting discussions that may help to add
depth to some of the Top 10 questions prioritised in our
study. Another prioritisation exercise to identify research
priorities for trial retention amongst Chief Investigators
identified similar priorities in its Top 10 list [8]. This in-
volved primarily use of routinely collected data (ranked
third in their study and second in ours), but they also iden-
tified several priorities (e.g. frequency and timing of re-
minders, time to complete questionnaire, mode of delivery
of questionnaire) that could all sit across several of our Top
10 questions. These two studies are complementary, but it
is important to note the key difference with our study: the
involvement of patients as participants to help identify and
set the research priorities. We believe this is a key strength
of our work, as recent work exploring the reasons why pa-
tients drop out of trials suggests that many of the reasons
could be negated through improved patient involvement in
the trial design and delivery [15].
Challenges encountered
An early challenge was the volume of data generated
using the six open-ended questions in the initial survey.




1 What motivates a participant’s decision to complete a
clinical trial?
2 How can trials make better use of routine clinical care
and/or existing data collection to improve retention?
3 How can trials be designed to minimise burden on staff
and participants and how does this affect retention?
4 What are the best ways to encourage trial participants
to complete the tasks (e.g. attend follow-up visits,
complete questionnaires) required by the trial?
5 How does involvement of patients/the public in planning
and running trials improve retention?
6 How could technology be best used in trial follow-up
processes?
7 What are the most effective ways of collecting information
from participants during a trial to improve retention?
8 How does a participant’s ongoing experience of the trial
affect retention?
9 What information should trial teams communicate to
potential trial participants to improve trial retention?
10 How should people who run trials plan for retention
during their funding application and creation of the trial
(protocol development)?
Fig. 1 PRioRiTy II priority setting partnership process
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As we thematically coded and sorted responses during
analysis, where a response could contain multiple the-
matic items and questions within a single answer, we
were inevitably faced with the total number of data items
being an order of magnitude larger than the total num-
ber of initial responses. This type of process of data cod-
ing introduces the potential for bias to have been
introduced through coder variation, which is a problem
for survey research [18]. To mitigate the problem of
coder variation, the Aberdeen team worked to ensure a
true representation of the data and also conducted the
necessary checks and discussions where there was dis-
agreement to ensure the methodological reliability and
integrity of the data. We sorted the data so that the con-
nection between individual data items and the final
question list was maintained and could be easily viewed
and traced. This allows us to demonstrate how initial
survey responses were developed into the final priority
question list through each stage of this project.
Another challenge faced was the possibility that in-
cluding examples within a question might influence
how the question was interpreted. We sought a balance
between ensuring that the questions were clearly ex-
plained and trying to avoid unduly influencing their
meaning and interpretation. For this reason, and in
specific instances, we decided, in discussion with the
Steering Group, to give brief examples within questions
that might otherwise be hard to understand. However,
it was clear from observations of the small group dis-
cussions during the consensus meeting that groups in
some instances focussed on the examples more than
the category the examples represented. In the future, if
examples are included within a question, it should be
made clear that they are not intended to cover the
whole scope of the question, and should not encourage
direct answers from the consensus meeting partici-
pants. Although, where appropriate, the JLA facilitators
and some group participants did point out the differ-
ence, it is possible that some people chose to interpret
and therefore rank the questions on that basis. In the
final ordered question list, the questions ranked in the
bottom six positions (16–21) all featured examples.
This framing effect is known to be a problem in survey
research [19]. As such, this calls into question whether
these examples limited the perceived potential scope of
the research question and affected stakeholders’ under-
standing of their comparative importance.
A concern during this project was the potential for
one stakeholder group to unduly influence another
due to having more extensive knowledge and
Table 5 Question overlap across PRioRiTy PSPs
PRioRiTy I ranking PRioRiTy II ranking Research question
A 6 What are the key motivators influencing members
of the public’s decisions to take part in a
randomised trial?
1 What motivates a participant’s decision to
complete a clinical trial?
B 1 How can randomised trials become part of
routine care and best utilise current
clinical care pathways?
2 How can trials make better use of routine
clinical care and/or existing data collection
to improve retention?
C 3 Does patient/public involvement in
planning a randomised trial
improve recruitment?
5 How does involvement of patients/the
public in planning and running trials
improve retention?
D 10 What are the advantages and disadvantages
to using technology during the recruitment process?
6 How could technology be best used in trial
follow-up processes?
E 2 What information should trialists communicate
to members of the public who are being invited
to take part in a randomised trial in
order to improve recruitment to the trial?
9 What information should trial teams communicate
to potential trial participants to improve trial retention?
The rows highlighted represent the priorities identified for trial retention
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experience of trial methodology. This could be exac-
erbated by the difficulties in advertising the project to
patients and carers who are unfamiliar with research
terminology. At each stage, we acted to ensure that
researchers and trial methodologists, who made up a
majority of responders during the initial and interim
phases, did not overshadow the input of patients and
members of the public. This required regular check-
ing of survey response totals to inform our audience
targeting, as well as utilising a weighted system of
point allocation during the interim survey ranking to
provide a balanced perspective of respondent views.
We also took steps to ensure that the research
remained easily accessible and understandable to all
stakeholders during the course of the project. These
steps included working closely with the Steering Group
during the initial stage to combine similar questions and
conducting ‘back-categorisation’ on the terminology of re-
search questions that were generated at the interim stage.
We also deliberately omitted titles and job descriptions
from name badges at the final consensus meeting to pro-
mote equity between the stakeholder groups. Further, the
guidance of experienced JLA facilitators promoted a re-
spectful discussion with equal participation. For this entire
process the input and contribution of our patient partners
was invaluable, as they provided guidance and feedback
throughout the PSP. The involvement of patient partners
enriched the methods and results of this project.
It is worth noting that the reductionist approach to
combining stakeholder sub-groups into four overarching
groups may have resulted in some key differences between
these smaller sub-groups being missed. For example, per-
haps the opinions of patients actively involved in research
as partners varied compared to those of patients who had
been involved in trials as participants; likewise, Trial Man-
agers’ perspectives could have differed from those of Re-
search Nurses. However, given the overall purpose of the
project was to reach consensus across the groups, these
specific differences between groups are of less importance
than the overall agreement on the research agenda.
During the final consensus meeting, one issue encoun-
tered was maintaining the topic of discussion to be fo-
cussed on retention rather than branching out onto
issues of recruitment, as these two subjects overlap con-
siderably. The experience of the JLA facilitators was in-
dispensable to direct conversation back to the topic and
question at hand. This allowed members of the Steering
Group and research team to act as impartial observers
unless asked to clarify a point by the JLA facilitator,
though clarifications were rarely required. Through
these combined efforts, we believe we were able to
accurately and fairly represent the views of stake-
holders, taking due consideration for patient and
public contributors, and create an equal opportunity
for all to affect the project outcome. Our experi-
ences of communicating and involving members of
the public as stakeholders for this meeting are in
line with existing research [11, 20–22] in that a flex-
ible approach and quick response were essential.
Implications
Through our approach, this PSP has successfully identi-
fied uncertainties and unanswered research questions on
retention in randomised trials. This now provides a plat-
form for future research projects on retention in trials to
build upon, and creates a credible methodological ap-
proach to the selection of these research topics. This can
provide a higher level of certainty for both funders and
research organisations that the questions identified in
this project are critical to address in any effort to im-
prove retention in trials and reduce research waste [9].
When viewed with PRioRiTy I, we are able to give direc-
tion to future research into two of the top three research
priorities identified by the UK clinical trials community
[1]. Future research to address the third priority, choos-
ing appropriate outcomes to measure, would benefit
from a similar approach as reported here such as the
Core Outcome Measures in Effectiveness Trials
(COMET) Initiative, which uses a similar method of Del-
phi survey and consensus meeting to develop agreed
standardised sets of outcomes for clinical trials, known
as ‘core outcome sets’ [23]. Furthermore, by viewing the
results of both of these PSPs thematically, we can ob-
serve the overlap between uncertainties across retention
and recruitment to randomised trials, as well as specific
topic areas stakeholders view as important.
Conclusions
This PRioRiTy II PSP found that the key stakeholders
involved in randomised trials such as staff, researchers,
and patients/public believe future research on improve-
ments to retention should focus primarily on individual
motivation to complete trials, how trials can better use
routine clinical care and existing data collection path-
ways, and how burden to participants can be minimised
through trial design. Addressing these concerns is cen-
tral to any sincere effort to investigate retention within
trials as well as more efficiently provide a benefit to pa-
tients and others who use our health services. The
complete 21-question list will be hosted online at www.
priorityresearch.ie and will be further grouped into the
thematic comparisons generated by the previous PRioR-
iTy I PSP on recruitment.
Researchers are encouraged to build proposals addressing
the questions raised. We also encourage funders to incorp-
orate these research priorities into their current strategies
to address issues with randomised trial retention. We also
highly valued having patients and carers as our research
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partners throughout this project and advocate their contri-
bution as essential for future research into trial retention
and trial methodology.
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Appendix 2




11 What aspects of trial recruitment processes could be changed to improve retention?
12 What aspects of trial retention do participants perceive as burdensome, and how can these be addressed?
13 What influence does the relationship between trial staff and participants have on retention?
14 How does a sense of belonging or being part of something amongst trial participants affect retention?
15 What are the best approaches for designing and communicating information about trial retention for trial participants?
16 To what extent (if any) do studies that explore retention procedures before the main trial (i.e. feasibility study) lead to improvements
in retention in the main trial?
17 What is the impact of timing, frequency, and duration of follow-up (e.g. questionnaires, clinic appointments) on retention?
18 What strategies (e.g. sending Christmas cards or saying ‘thank you’) make participants feel valued and how do they affect retention?
19 What are the best strategies for using participant incentives (e.g. monetary or non-monetary), and how should they be implemented
(e.g. when should they be provided) when collecting information from participants in clinical trials?
20 How does continuity (e.g. seeing/speaking to the same staff) and consistency (e.g. of trial information) affect retention?
21 What behaviours of trial staff (e.g. being friendly) result in improved retention?
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